Author Archives: SetLance
Date: 13th-16th April 2019
Location/Venue: Amsterdam, Netherlands
Prof. Alessandro Pini "The antimicrobial peptide SET-M33. A case of preclinical drug development"
The development of a synthetic branched peptide for fighting multi-resistant Gram-negative bacteria.
Speaker: Alessandro Pini,
Conference website: http://berlin-conferences.com/home/
Seal of Excellence 2017
Certificate delivered by the European Commission, as the institution managing Horizon 2020, the EU Framework Programme for Research and Innovation 2014-2020 for the project "Non-clinical development of an antimicrobial drug to fight against resistant bacteria". The project has been presented in the area dedicated to supporting biotechnology of SMEs closing the gap from lab to market following evaluation by an international panel of independent experts. SetLance was scored as a high-quality project proposal in a highly competitive evaluation process.
Date: 22-25 April 2017
Location/Venue: Vienna, Austria
Two oral presentations:
Dott. Chiara Falciani "An antimicrobial peptide to face multidrug-resistance emergency: synergies and mechanism of action underpinning efficacy".
Dott. Alessandro Pini "The peptide SET-M33 as novel agent to neutralize and remove LPS in patients with sepsis".
The article ''A new hope for treating severe pneumonia'' featuring Setlance's antimicrobial peptide M33 was published on CORDIS (Community Research and Development Information Service), the European Commission’s primary public repository and portal to disseminate information on EU-funded research projects.
Read the whole article here:
October 2015. SetLance finances a PhD position in Biochemistry and Molecular Biology, XXXI cycle of the regional doctorate "Pegasus" (http://www.unisi.it/didattica/post-laurea/dottorati-ricerca/biochimica-e-biologia-molecolare-3). The selected student will be trained in SetLance laboratories working on projects related to the characterization and development of antimicrobial and anti-inflammatory peptides.
The BEAM Alliance urges European and national public authorities to take three key short term actions with immediate effect: (1) create a specific fund dedicated to small and medium biopharmas developing innovative antibacterial products, (2) enhance market incentives to increase the Return on Investment for products tackling antimicrobial resistance through the creation of a special status, (3) simplify regulatory pathways for products tackling antimicrobial resistance.
Recent developments in Bacterial Diseases, Bacteriology and Infectious Diseases.
Date: March 2015
Launch of BEAM Alliance – Biotechs of Europe innovating againts Anti-Microbial resistance
The BEAM Alliance intends to:
•Regroup European emerging biotech companies who are involved in developing innovative products to tackle antimicrobial resistance ;
•Represent them with a unique voice to propose and support policies and regulatory solutions to member-identified problems;
In order to reinforce the attractiveness of this therapeutic area, support the development of new products and accelerate market access of such new products for the European patients. The Group seeks to collaborate with the existing community of stakeholders dedicated to implementing tangible solutions to combat this serious public health issue. Our mission is to recommend incentives that warrant further consideration and action to policymakers and others to overcome these challenges and address the threat of antibacterial resistance, now and in the future.